Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab plus gemcitabine and oxaliplatin versus rituximab plus gemcitabine and oxaliplatin in relapsed/refractory diffuse large B-cell lymphoma
2023-506899-27-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoint: Overall survival. Planned start Mar 2021; status: authorised.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-506899-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506899-27-00.